Akston Biosciences Signs Licensing Agreement with Dechra Pharma
for AKS-425c, a Once-a-Week Insulin Therapy for Cats
Background: For the treatment of diabetes mellitus (DM) in dogs, novel insulins with decreased injection frequency while maintaining safety and efficacy are desirable. Insulin fused with immunoglobulin-fragment-crystallizable (Fc) has an ultra-long plasma half-life because it recycles through cells, protected from proteolysis.
READ THE ARTICLE